[1]阚 通,郭 俊,陈 亮,等.经皮室间隔心肌化学消融术治疗老年梗阻性肥厚型心肌病临床疗效及安全性[J].介入放射学杂志,2015,(11):946-949.
　KAN Tong,GUO Jun,CHEN Liang,et al.Percutaneous transluminal septal myocardial chemical ablation for the treatment of hypertrophic obstructive cardiomyopathy in aged patients： its clinical efficacy and safety[J].journal interventional radiology,2015,(11):946-949.

点击复制

经皮室间隔心肌化学消融术治疗老年梗阻性肥厚型心肌病临床疗效及安全性 ()

PDF下载中关闭

• 
• 
• 

分享到：

参考文献/References:

［1］ Lopes LR, Zekavati A, Syrris P, et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high- throughput sequen- cing［J］. J Med Genet, 2013, 50: 228- 239.
［2］ McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: an important cause of sudden death［J］. Arch Dis Child, 1984, 59: 971- 975.
［3］ Stewart JT, McKenna WJ. Management of arrhythmias in hypertrophic cardiomyopathy［J］. Cardiovasc Drugs Ther, 1994, 8: 95- 99.
［4］ Maron BJ, Maron MS. Hypertrophic cardiomyopathy［J］. Lancet,2013, 381: 242- 255.
［5］ Kimmelstiel C, Krishnamurthy B, Weintraub A, et al. Alcohol septal ablation and hypertrophic cardiomyopathy［J］. Zhonghua Xin Xue Guan Bing Za Zhi, 2009, 37: 1074- 1077.
［6］ 肥厚型梗阻性心肌病室间隔心肌消融术中国专家共识组. 肥厚型梗阻性心肌病室间隔心肌消融术中国专家共识［J］. 中国医药科学， 2012， 2： 5- 6.
［7］ Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines［J］. J Am Coll Cardiol, 2003, 42: 1687- 1713.
［8］ Maron BJ. Hypertrophic cardiomyopathy. A systematic review［J］. JAMA, 2002, 287: 1308- 1320.
［9］ Kuhn H, Seggewiss H, Gietzen FH, et al. Catheter- based therapy for hypertrophic obstructive cardiomyopathy. First in- hospital outcome analysis of the German TASH Registry［J］. Z Kardiol, 2004, 93: 23- 31.
［10］ Zeng Z, Wang F, Dou X, et al. Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy a meta analysis［J］. Int J Cardiol, 2006, 112: 80- 84.
［11］ Sigwart U. Non- surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet, 1995, 346: 211- 214.
［12］ 赵林阳， 王大伟， 杨 平， 等． 经导管化学消蚀心肌治疗肥厚性梗阻型心肌病（附一例报告）［J］． 中华心血管病杂志， 1998， 26： 70- 71．
［13］ 张 明， 李占全， 金元哲， 等． 经皮经腔间隔心肌化学消融术治疗肥厚型梗阻性心肌病两年疗效观察［J］． 中华心血管病杂志， 2003， 31： 45- 48．
［14］ 李占全， 张 明， 关汝明， 等． 经皮经冠状动脉室间隔化学消融术治疗梗阻性肥厚型心肌病的近期疗效观察［J］． 中华心血管病杂志， 2001， 29： 8- 11．
［15］ Lyne JC, Kilpatrick T, Duncan A, et al. Long- term follow- up of the first patients to undergo transcatheter alcohol septal ablation［J］. Cardiology, 2010, 116: 168- 173.
［16］ Leonardi RA, Kransdorf EP, Simel DL, et al. Meta- analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy comparative rates of overall mortality and sudden cardiac death after treatment［J］. Circ Cardiovasc Interv, 2010, 3: 97- 104.
［17］ Aslam F, Haque A, Foody J, et al. The frequency and functional impact of overlapping hypertension on hypertrophic cardiomyo- pathy: a single- center experience［J］. J Clin Hypertens （Greenwich）, 2010, 12: 240- 245.
［18］ Wang Y, Zhou XO, Zhang Y, et al. Association of the CD36 gene with impaired glucose tolerance, impaired fasting glucose, type- 2 diabetes, and lipid metabolism in essential hypertensive patients［J］. Genet Mol Res, 2012, 11: 2163- 2170.
［19］ Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology（ESC）［J］. Eur Heart J, 2014, 35: 2733- 2779.
［20］ 李成洋， 张薇薇， 李占全， 等． 70岁以上肥厚性梗阻型心肌病患者化学消融的安全性初探［J］． 中国循环杂志， 2012， 27： 186- 188．